Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Wyeth announces availability of Xyntha

Wyeth announces availability of Xyntha

9th September 2008

Wyeth Pharmaceuticals, a division of Wyeth, has announced the availability of Xyntha (Antihaemophilic Factor [Recombinant], plasma/albumin-free) as a treatment for patients with haemophilia A.

The drug is a new recombinant factor VIII product indicated to control and prevent bleeding episodes and surgical prophylaxis in patients with this hereditary disease.

Wyeth said the compound is produced using a state-of-the-art purification and manufacturing process to reduce the risk of viral contamination, using a unique synthetic ligand free of animal materials.

The process also includes a nanofiltration step which utilises a 35 nanometre pore-size filter.

Wyeth said shipments of ReFacto Antihaemophilic Factor (Recombinant) would cease in the US at the end of May 2009.

Robert Repella, executive vice-president and general manager of Wyeth BioPharma, said: “We believe the state-of-the-art manufacturing and purification processes used for Xyntha make it an exciting new therapeutic option for many patients with haemophilia A.”

He added the introduction of the compound marks the endpoint of many years of research and development and underlines the company’s ongoing dedication to patients with haemophilia.

In February 2008, Wyeth said Xyntha is the only recombinant factor VIII product to use an entirely synthetic purification process when being manufactured.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.